Press Release

Antimalarial Drugs Market to Witness Robust Growth until 2025

Rising prevalence of malaria and COVID-19 to drive global antimalarial drugs market


According to TechSci Research report, Global Antimalarial Drugs Market By Drug Type (Quinine, Chloroquine, Proguanil, Amodiaquine, Mefloquine, Hydroxychloroquine, Pyrimethamine, Others), By Drug Class (Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, Antimicrobials), By Route of Administration (Oral, Powder Inhalation, Intravenous Administration), By Malaria Type (Plasmodium Falciparum, Plasmodium Malariae, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Knowlesi), By Application (Prevention, Treatment of Malaria), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce, Others), By Region, Forecast & Opportunities, 2025, the market is anticipated to witness robust CAGR during the forecast period. Key factors driving the global antimalarial drugs market include rising prevalence of malaria, especially in developing nations and increasing patient deaths from malaria. Also, the exponential increase in COVID-19 cases around the globe is a major factor fueling the growth of this market as chloroquines are anticipated to possess the ability to limit the virus spread. With hydroxychloroquine being a potential treatment for coronavirus, the market is witnessing a robust demand across various nations. Moreover, spike in research for new antimalarial drugs are acting augmenting the market growth. The governments’ focus on the treatment of COVID-19 is expected to boost the antimalarial drugs market growth through 2025.

Additionally, rise in healthcare expenditure and availability of wide range of antimalarial drugs are some other key factors propelling the growth of global antimalarial drugs market. However, the market might also face some challenges. The side-effects of anti-malarial drugs in many cases might hamper the market growth. Furthermore, the growing penetration of counterfeit and substandard drugs are anticipated to restrain the market growth in the coming years.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on "Global Antimalarial Drugs Market"

https://www.techsciresearch.com/report/antimalarial-drugs-market/5012.html

The global antimalarial drugs market is segmented based on drug type, drug class, route of administration, malaria type, application, distribution channel and region. Based on drug type, the market can be segmented into quinine, chloroquine, proguanil, amodiaquine, mefloquine, hydroxychloroquine, pyrimethamine and others. Among them, the hydroxychloroquine drugs are anticipated to register fastest growth and are expected to dominate the global market through 2025, which can be attributed to spike in cases of COVID-19 around the world and increasing usage of hydroxychloroquine for the treatment of virus affected patients.

Based on malaria type, the global antimalarial drugs market is segmented into plasmodium falciparum, plasmodium malariae, plasmodium vivax, plasmodium ovale and plasmodium knowlesi. Among them, the plasmodium falciparum segment is anticipated to dominate the market during the forecast period as a large part of world population is heavily exposed to the bites of mosquitoes and is at risk of getting infected with plasmodium falciparum. Moreover, lack of access to healthcare facilities and increasing pool of people with low immunity towards malaria is driving the growth of this segment.

Major players operating in the global antimalarial drugs market include F. Hoffmann-La Roche Ltd, Alvizia Healthcare Pvt. Ltd., Bayer AG, Cipla Limited, GlaxoSmithKline Plc, Ipca Laboratories Ltd., Mayne Pharma Group Limited, Merck & Co., Inc, , King Pharmaceuticals, Inc, Novartis AG, Zydus Cadila, Sanofi S.A., Pfizer Inc., Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories), Strides Pharma Science Limited, Glenmark Pharmaceuticals and Lincoln Pharmaceuticals. The manufacturers are focusing on new product launches, partnerships and acquisitions to strengthen their position in global antimalarial drugs market.

Download Sample Report  @ https://www.techsciresearch.com/sample-report.aspx?cid=5012

Customers can also request for 10% free customization on this report.

“India is one of the leading countries which has a strong presence of pharmaceutical companies manufacturing hydroxychloroquine. Countries reeling under COVID-19 cases are demanding hydroxychloroquine from India, thereby pushing Indian government to increase the exports of antimalarial drugs. Manufacturers are increasing their production capacities and are already producing over 1.5 million tablets on a daily basis,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

Global Antimalarial Drugs Market By Drug Type (Quinine, Chloroquine, Proguanil, Amodiaquine, Mefloquine, Hydroxychloroquine, Pyrimethamine, Others), By Drug Class (Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, Antimicrobials), By Route of Administration (Oral, Powder Inhalation, Intravenous Administration), By Malaria Type (Plasmodium Falciparum, Plasmodium Malariae, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Knowlesi), By Application (Prevention, Treatment of Malaria), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce, Others), By Region, Forecast & Opportunities, 2025” has evaluated the future growth potential of global antimalarial drugs market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global antimalarial drugs market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

 

Tel: +1-646-360-1656

 

Email: [email protected]

 

Relevant News